Trial Profile

Prospective Multicenter Observational Study of Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic Non-small Cell Lung Cancer: (J-TAIL)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 14 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Aug 2022 Results (n=1039) assessing the long-term effectiveness and safety of atezolizumab monotherapy in patients with unresectable advanced or recurrent NSCLC under real-world settings in Japan and results of blood-based biomarker studies were conducted as exploratory research, presented at the 2022 World Conference on Lung Cancer.
20 Jul 2022 Status changed from active, no longer recruiting to completed.
02 Jul 2021 Planned End Date changed from 15 Jun 2022 to 16 Apr 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com